Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

Study identifier:D0817R00011

ClinicalTrials.gov identifier:NCT04560452

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Olaparib in Clinical Practice Among Chinese Patients.

Medical condition

ovarian cancer

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

1000

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 11 Jun 2021
Estimated Primary Completion Date: 30 Apr 2025
Estimated Study Completion Date: 30 Apr 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria